Drug Profile
Research programme: antipsychotics - Cenomed BioSciences
Alternative Names: CM-2,303; CM-2,393Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cenomed BioSciences LLC
- Developer Cenomed BioSciences
- Class
- Mechanism of Action 5-HT1A serotonin receptor agonists; Alpha-1a adrenergic receptor antagonists; Dopamine D2 receptor modulators; Dopamine D3 receptor agonists; Dopamine D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO)
- 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
- 19 Nov 2008 Preclinical pharmacodynamics data presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,